Japanese researchers have discovered that giant-nucleus cells surviving iron-induced cellular damage form the foundation of early-stage cancer. Published in the journal Redox Biology by a Nagoya University team, the findings show these distinct cells could serve as accessible microscopic biomarkers to predict patient outcomes.
Scientists have tracked abnormal cells with enlarged nuclei in the early phases of cancer since the 1980s. Until recently, however, the precise role these cells played in cancer development remained unclear.
Mapping Iron-Induced Damage and Giant-Nucleus Cell Survival
Iron is an essential micronutrient, but excess iron damages cells and elevates cancer risk. While many cells succumb to iron-induced oxidative stress, a specific subset survives and may eventually become malignant. A Japanese research team has demonstrated that these surviving giant-nucleus cells form the foundation of early-stage cancer.
To investigate this phenomenon, researchers injected ferric nitrilotriacetate, a carcinogenic iron compound, into rats to induce kidney damage. They then collected tissue samples before the injection and at one and three-week intervals afterward. The team deployed spatial transcriptomics to map gene activity in individual cells while preserving structural integrity. They also conducted computational analyses to quantify nuclear size, shape, and density.
Within one week of iron administration, giant-nucleus cells emerged. These cells upregulated cancer-related genes such as Myc and Met while developing resistance to ferroptosis, an iron-dependent form of cell death. Furthermore, the study used two groups: wild-type rats and rats carrying a single mutated BRCA1 gene. BRCA1-deficient rats developed giant-nucleus cells with distinct biological profiles, suggesting that impaired DNA repair allows a greater number of precancerous giant-nucleus cells to survive.
Classifying Nuclear Profiles and Mitochondrial Remodeling
By analyzing gene activity and nuclear morphology, the research team classified giant-nucleus cells into six distinct types. One category showed extremely large nuclei alongside signs of stress-induced growth arrest. Another category, observed more frequently in BRCA1-mutant kidneys, displayed elevated cancer-related gene activity and elongated nuclei, indicating a potential precancerous state.
Through electron microscopy and cellular respiration measurements, investigators confirmed that cells from BRCA1-mutant rats underwent mitochondrial remodeling. This structural shift resulted in impaired iron handling and compromised respiratory function.
Even morphologically normal cells situated near giant-nucleus cells exhibited gene expression changes that could promote survival. In addition, kidney tissue from BRCA1-mutant rats showed a substantial increase in stromal cells around damaged regions, pointing to a heavily altered local tissue environment.
Connecting Animal Models to Human Patient Outcomes
To test whether these laboratory findings translate to humans, the researchers analyzed data from the TCGA-KIRC, a large public database of kidney cancer patients. Patients whose tumors shared gene expression patterns with cancer-prone giant-nucleus cells experienced shorter survival times. Conversely, those sharing patterns with healthier giant-nucleus cells achieved better outcomes, indicating that not all giant-nucleus cells carry identical risk.
In a small pilot study, the research team also examined human tissue samples. They observed similar abnormal nuclear features in breast tissue taken from seven individuals with inherited BRCA1 mutations, compared to 15 non-carriers.
Altogether, the morphological analysis examined 7,662 ductal epithelial nuclei, comprising 2,141 nuclei from BRCA1 mutation carriers and 5,521 from non-carriers. Within the BRCA1-mutant group, the activity of the cancer-associated Karyo2 transcriptional program correlated strongly with nuclear eccentricity, while the shared KaryoCore program correlated with nuclear solidity.
Unresolved Questions and Future Research Directions
While the study establishes a link between giant-nucleus cells and early carcinogenesis, major questions remain unanswered. Long-term studies will be required to track how giant-nucleus cells specifically develop into tumor cells and whether targeting mitochondrial changes or ferroptosis resistance can prevent cancer formation.
Researchers must also determine whether nuclear shape and gene expression patterns can effectively diagnose or predict kidney cancer in larger patient groups, moving biomarker research from animal models closer to clinical application.